한글목차

약제 요약

OSE-2101(Tedopi)은 OSE Immunotherapeutic의 최첨단 제품인 치료용 네오에피토프 기반 백신으로, T세포를 특이적으로 활성화하는 5가지 종양 항원으로부터 선별되고 최적화된 9개의 네오에피토프와 T세포 활성화를 표적으로 하는 만능 T세포 반응을 제공하는 하나의 헬퍼 T세포 반응을 유도하는 하나의 에피토프(epitope)를 독자적으로 조합한 테도피는 세포독성 반응의 중요한 수용체인 HLA-A2 환자를 위해 설계된 치료제입니다.

현재 테도피는 종양학 협력단체인 ARCAGY-GINECO의 지원을 받아 백금 민감성 재발성 난소암 환자를 대상으로 백금 기반 화학요법 후 질병이 조절된 경우, 유지요법으로 단독 또는 항 PD-1제제 키트루다와 병용하여 최선의 지지요법으로 평가하기 위해 3군으로 구성된 TEDOVA 임상 2상 시험이 진행 중입니다. 으로 단독 또는 항 PD-1 치료제 키트루다와 병용하여 최선의 지지요법과 비교 평가되고 있습니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 난소암용 OSE-2101에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 난소암에서 OSE-2101의 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 OSE-2101 시장 평가

• 난소암에서 OSE-2101의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장의 난소암용 OSE-2101의 시장 규모
• 시장 분석 : 국가별
  • 미국의 난소암용 OSE-2101의 시장 규모
  • 독일의 난소암용 OSE-2101의 시장 규모
  • 영국의 난소암용 OSE-2101의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"OSE-2101 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OSE-2101 for ovarian cancer in the seven major markets. A detailed picture of the OSE-2101 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the OSE-2101 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OSE-2101 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

OSE-2101 (Tedopi) - OSE Immunotherapeutic's most advanced product and therapeutic neo-epitope-based vaccine - is a proprietary combination of nine optimized neo-epitopes, selected and optimized from five tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell activation. It is a treatment designed for HLA-A2+ patients, a key receptor of the cytotoxic response.

Currently, Tedopi is being studied in a three-arm TEDOVA Phase II study, which is evaluating it as a maintenance treatment, alone or in combination with the anti-PD-1 KEYTRUDA, versus the best supportive care in platinum-sensitive recurrent ovarian cancer patients, with the controlled disease after platinum-based chemotherapy under the sponsorship of cooperative group in oncology ARCAGY-GINECO.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the OSE-2101 description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on OSE-2101 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OSE-2101 research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around OSE-2101.
• The report contains forecasted sales of OSE-2101 for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for OSE-2101 in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OSE-2101 Analytical Perspective by DelveInsight

• In-depth OSE-2101 Market Assessment

This report provides a detailed market assessment of OSE-2101 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• OSE-2101 Clinical Assessment

The report provides the clinical trials information of OSE-2101 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OSE-2101 dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to OSE-2101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OSE-2101 in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of OSE-2101 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OSE-2101 in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of OSE-2101?
• What is the clinical trial status of the study related to OSE-2101 in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OSE-2101 development?
• What are the key designations that have been granted to OSE-2101 for ovarian cancer?
• What is the forecasted market scenario of OSE-2101 for ovarian cancer?
• What are the forecasted sales of OSE-2101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to OSE-2101 for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. OSE-2101 Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. OSE-2101 Market Assessment

• 5.1. Market Outlook of OSE-2101 in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of OSE-2101 in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of OSE-2101 in the United States for ovarian cancer
  • 5.3.2. Market Size of OSE-2101 in Germany for ovarian cancer
  • 5.3.3. Market Size of OSE-2101 in France for ovarian cancer
  • 5.3.4. Market Size of OSE-2101 in Italy for ovarian cancer
  • 5.3.5. Market Size of OSE-2101 in Spain for ovarian cancer
  • 5.3.6. Market Size of OSE-2101 in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of OSE-2101 in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options